Network News

Uppsala, Sweden, 05 February 2025: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers, today announced the introduction of its Gyrolab® HEK293 HCP Type SN Kit Reagents and Gyrolab HEK293 HCP Type CL Kit Reagents. Developed with antibodies from BioGenes GmbH, a global leader in host cell protein (HCP) assay […]

The research of BioMed X team EDC – Extrachromosomal DNA in Cancer – has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for novel cancer therapies. Heidelberg, Germany, February 6, 2025. BioMed X, a German independent research institute, announces the successful completion of its oncology research project in partnership […]

Three institutions have joined our consortium as official Chemoproteomics and Spatial Mass Spectrometry (MS)-Based Omics partner sites, enhancing the services we can offer to the research community in the areas of target identification and validation. Phil Gribbon, Director General of EU-OPENSCREEN, emphasised: “The three new chemoproteomics sites joining the EU-OPENSCREEN partner network provide a significant boost […]

Braunschweig, January 29th, 2025 – YUMAB GmbH, a German biotechnology company specializing in contract research for therapeutic antibodies, announces its collaboration with InSCREENeX GmbH to establish a novel technology for antibody development. As part of the funded project “Mammalian Display,” the two Braunschweig-based companies are developing a platform that enables the screening of antibody libraries […]

Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging […]

Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation / exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing efficacy and safety of bemdaneprocel in people living with moderate Parkinson’s disease / Expected to be initiated in H1 2025, exPDite-2 is […]

Heidelberg, Germany, January 14, 2025. BioMed X, an independent biomedical research institute based in Heidelberg, Germany, announced today the launch of a new collaboration with Daiichi Sankyo Co., Ltd., a global pharmaceutical company headquartered in Japan. This collaboration marks the start of a cutting-edge initiative to explore innovative approaches in cancer treatment using multi-specific biologics. The new […]

Ladenburg, Germany, 13 January 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it is advancing into Cohort 7 in a Phase I/IIa dose escalation study with lead ATAC candidate HDP-101 for the treatment of relapsed or refractory multiple myeloma. Previously, in Cohort 6, dose […]

Non-viral platform for efficient drug transfer to facilitate clinical developments Heidelberg, 15.01.2025 – PROGEN, leading manufacturer of Adeno-Associated-Virus (AAV) analytical tools for gene therapy research and development, announces the launch of LNPs for the versatile delivery of therapeutic agents into cells. In the past decade, PROGEN has driven progress in gene therapy by providing reliable […]